Compounds > lasonolide a
Page last updated: 2024-11-12

lasonolide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lasonolide A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11342965
CHEMBL ID56091
SCHEMBL ID1231082
MeSH IDM0419130

Synonyms (4)

Synonym
lasonolide a
CHEMBL56091
SCHEMBL1231082
DTXSID901043969

Research Excerpts

Overview

Lasonolide A (LSA) is a natural product with high and selective cytotoxicity against mesenchymal cancer cells, including leukemia, melanomas and glioblastomas.

ExcerptReferenceRelevance
"Lasonolide A is a novel polyketide displaying potent anticancer activity across a broad range of cancer cell lines. "( A concise synthesis of (-)-lasonolide A.
Fandrick, DR; Huang, A; Hull, KL; Stivala, CE; Trost, BM, 2014)		2.14
"Lasonolide A (LSA) is a natural product with high and selective cytotoxicity against mesenchymal cancer cells, including leukemia, melanomas and glioblastomas. "( Lasonolide A, a potent and reversible inducer of chromosome condensation.
Ghosh, AK; Pommier, Y; Zhang, YW, 2012)		3.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID80524Concentration required for growth inhibition human of human colon cancer cell line HCT1162002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthesis of (+)-Lasonolide A: (-)-lasonolide A is the biologically active enantiomer.
AID80530Growth inhibition against HCT116 cell line was evaluated2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Synthesis and evaluation of lasonolide A analogues.
AID333101Cytotoxicity against human NCI/ADR-RES cells2004Journal of natural products, Aug, Volume: 67, Issue:8
Lasonolides C-g, five new lasonolide compounds from the sponge Forcepia sp.
AID333100Cytotoxicity against human PANC1 cells2004Journal of natural products, Aug, Volume: 67, Issue:8
Lasonolides C-g, five new lasonolide compounds from the sponge Forcepia sp.
AID143020Concentration required for growth inhibition of human lung carcinoma cell line NCI-H4602002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthesis of (+)-Lasonolide A: (-)-lasonolide A is the biologically active enantiomer.
AID333099Cytotoxicity against human A549 cells2004Journal of natural products, Aug, Volume: 67, Issue:8
Lasonolides C-g, five new lasonolide compounds from the sponge Forcepia sp.
AID8472Concentration required for growth inhibition of human lung carcinoma cell line A5492002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthesis of (+)-Lasonolide A: (-)-lasonolide A is the biologically active enantiomer.
AID145208Growth inhibition against NCI-H460 cell line was evaluated2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Synthesis and evaluation of lasonolide A analogues.
AID8474Growth inhibition against A549 cell line was evaluated2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Synthesis and evaluation of lasonolide A analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (57.89)29.6817
2010's6 (31.58)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.10 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.1110pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
thiazoles
[no description available]		2.05101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
ruthenium
Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.		2.5220iron group element atom;
platinum group metal atom
alkenes
[no description available]		2.1310
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0510organic bromide saltcolorimetric reagent;
dye
sorafenib
[no description available]		2.1110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
azd 6244
AZD 6244: a MEK inhibitor		2.1110benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Pancreas
[description not available]		02.0510
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.0510